ABSTRACT
Introduction People with African ancestry have greater stroke risk and greater heritability of stroke risk than people of other ancestries. Given the importance of NO in stroke, we examined the association between alpha globin gene (HBA) copy number and incident ischemic stroke in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.
Methods Among 9,999 Black REGARDS participants9 with HBA and HBB genotyping available, 8,947 participants had no self-reported history of stroke at baseline and complete follow-up data. Incident ischemic stroke was defined as non-hemorrhagic stroke with a focal neurological deficit lasting ≥ 24 hours confirmed by the medical record or a focal or non-focal neurological deficit with positive imaging confirmed with medical records. Genomic DNA was analyzed using droplet digital PCR to determine HBA copy number. Multivariable Cox proportional hazards regression was used to estimate the hazard ratio (HR) of HBA copy number on time to first ischemic stroke.
Results Four-hundred seventy-nine (5.3%) participants had an ischemic stroke over a median (IQR) of 11.0 (5.7, 14.0) years’ follow-up. HBA gene copy number ranged from 2 to 6: 368 (4%) -α/-α, 2,480 (28%) -α/αα, 6,014 (67%) αα/αα, 83 (1%) ααα/αα and 2 (<1%) ααα/ααα. The HR of ischemic stroke with HBA copy number, adjusted for age, sex, hypertension, atrial fibrillation, LVH, diabetes, and smoking, was 1.04; 95%CI 0.89, 1.21; p = 0.66.
Conclusions Although a reduction in HBA copy number is expected to increase endothelial nitric oxide signaling in the human vascular endothelium, HBA copy number was not associated with incident ischemic stroke in this large longitudinal cohort of Black Americans. This finding is consistent with a prior study demonstrating no association between HBA copy number and hypertension but differs from a study demonstrating an association with chronic and end-stage kidney disease in which HBA gene deletions are protective. Together, these population studies suggest that the physiological roles of alpha globin may differ between the renal and cerebral vascular beds.
INTRODUCTION
People with African ancestry have greater stroke risk and greater heritability of stroke risk than people of other ancestries.1,2 While some risk is explained by genetic variants shared between European and African populations, less is known about African-specific variants.3 Alpha globin (HBA), which regulates endothelial nitric oxide (NO) signaling in resistance arteries, varies in gene copy number among people of African and Asian descent.4,5 Genetic deletion of HBA is associated with protection from kidney disease, possibly through increased vascular NO signaling.6 Given the importance of NO in stroke,7,8 we examined the association between HBA copy number and incident ischemic stroke in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.9
METHODS
Among 9,999 Black REGARDS participants9 with HBA and HBB genotyping available, 8,947 participants had no self-reported history of stroke at baseline and complete follow-up data (Figure S1) (additional methods in Supplemental Material). Incident ischemic stroke was defined as non-hemorrhagic stroke with a focal neurological deficit lasting ≥ 24 hours confirmed by the medical record or a focal or non-focal neurological deficit with positive imaging confirmed with medical records. Genomic DNA was analyzed using droplet digital PCR 6 to determine HBA copy number. Multivariable Cox proportional hazards regression was used to estimate the hazard ratio (HR) of HBA copy number on time to first ischemic stroke (see Supplemental Material). Pre-specified tests of interaction with age, sex, and sickle cell trait were and HBA copy number were performed on fully adjusted models. Pre-specified sensitivity analyses individually adding adjustment factors were performed: the first ten principal components of ancestry (PCA), HBA regulatory single nucleotide polymorphisms (SNP) rs11248850 and rs7203560, hemoglobin, chronic kidney disease (CKD), hemoglobin and CKD together, regular aspirin use, and regular statin use.
RESULTS
Four-hundred seventy-nine (5.3%) participants had an ischemic stroke over a median (IQR) of 11.0 (5.7, 14.0) years’ follow-up (Figure S1). HBA gene copy number ranged from 2 to 6: 368 (4%) -α/-α, 2,480 (28%) -α/αα, 6,014 (67%) αα/αα, 83 (1%) ααα/αα and 2 (<1%) ααα/ααα (Table S1). The HR of ischemic stroke with HBA copy number, adjusted for age, sex, hypertension, atrial fibrillation, LVH, diabetes, and smoking, was 1.04; 95%CI 0.89, 1.21; p = 0.66; (Table S2). There were no interactions between HBA copy number and age, sex, or sickle cell trait (Table S3). In pre-specified sensitivity analyses, the addition of hemoglobin, chronic kidney disease, aspirin use, statin use, or the first ten principal components of ancestry did not materially change the observed associations (Table S4.)
CONCLUSIONS
Although a reduction in HBA copy number is expected to increase endothelial nitric oxide signaling in the human vascular endothelium, HBA copy number was not associated with incident ischemic stroke in this large longitudinal cohort of Black Americans. This finding is consistent with a prior study demonstrating no association between HBA copy number and hypertension but differs from a study demonstrating an association with chronic and end-stage kidney disease in which HBA gene deletions are protective.6,10 Together, these population studies suggest that the physiological roles of alpha globin may differ between the renal and cerebral vascular beds.
Data Availability
Data are available from the University of Alabama (regardsadmin{at}uab.edu).
DATA AVAILABILITY
Data are available from the University of Alabama at Birmingham (regardsadmin{at}uab.edu). The genetic data is available in dbGaP with study accession number phs002719.v1.p1.
FUNDING
NIH U01 NS041588 (M.C.); AI001150 (H.C.A), HL006196 (H.C.A.); HHSN26120080001E (C.A.W); K08HL12510 (R.P.N.) and K08HL096841 (N.A.Z.).
DISCLOSURES
Dr. Gutierrez receives funding from GlaxoSmithKline; consulting fees from Reata, AstraZeneca, and Ardelyx; funding and consulting fees from Akebia Therapeutics, Amgen. He serves on a data monitoring committee for QED Therapeutics.
